Cargando…

A New ABCB1 Inhibitor Enhances the Anticancer Effect of Doxorubicin in Both In Vitro and In Vivo Models of NSCLC

In tumors, the multi drug resistance phenomenon may occur through the efflux of chemotherapeutic drugs out of cancer cells, impeding their accumulation, and eventually reducing their toxicity. This process is mediated by transporters overexpressed in the plasma membranes of tumor cells, among which...

Descripción completa

Detalles Bibliográficos
Autores principales:	Adorni, Maria Pia, Galetti, Maricla, La Monica, Silvia, Incerti, Matteo, Ruffoni, Alessandro, Elviri, Lisa, Zanotti, Ilaria, Papotti, Bianca, Cavallo, Delia, Alfieri, Roberta, Petronini, Pier Giorgio, Bernini, Franco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9861803/ https://www.ncbi.nlm.nih.gov/pubmed/36674503 http://dx.doi.org/10.3390/ijms24020989

Ejemplares similares

Interaction between Occupational and Non-Occupational Arsenic Exposure and Tobacco Smoke on Lung Cancerogenesis: A Systematic Review
por: Folesani, Giuseppina, et al.
Publicado: (2023)

Intrinsic Resistance to Osimertinib in EGFR Mutated NSCLC Cell Lines Induced by Alteration in Cell-Cycle Regulators
por: Volta, Francesco, et al.
Publicado: (2023)

Efficacy of the CDK4/6 Dual Inhibitor Abemaciclib in EGFR-Mutated NSCLC Cell Lines with Different Resistance Mechanisms to Osimertinib
por: La Monica, Silvia, et al.
Publicado: (2020)

Effect of ABCG2/BCRP Expression on Efflux and Uptake of Gefitinib in NSCLC Cell Lines
por: Galetti, Maricla, et al.
Publicado: (2015)

CDK4/6 Inhibition Enhances the Efficacy of Standard Chemotherapy Treatment in Malignant Pleural Mesothelioma Cells
por: Terenziani, Rita, et al.
Publicado: (2022)

Trastuzumab emtansine is active on HER-2 overexpressing NSCLC cell lines and overcomes gefitinib resistance
por: Cretella, Daniele, et al.
Publicado: (2014)

Gefitinib Inhibits Invasive Phenotype and Epithelial-Mesenchymal Transition in Drug-Resistant NSCLC Cells with MET Amplification
por: La Monica, Silvia, et al.
Publicado: (2013)

Pre-treatment with the CDK4/6 inhibitor palbociclib improves the efficacy of paclitaxel in TNBC cells
por: Cretella, Daniele, et al.
Publicado: (2019)

Dual Inhibition of CDK4/6 and PI3K/AKT/mTOR Signaling Impairs Energy Metabolism in MPM Cancer Cells
por: Bonelli, Mara, et al.
Publicado: (2020)

Simultaneous Combination of the CDK4/6 Inhibitor Palbociclib With Regorafenib Induces Enhanced Anti-tumor Effects in Hepatocarcinoma Cell Lines
por: Digiacomo, Graziana, et al.
Publicado: (2020)

Third generation EGFR inhibitor osimertinib combined with pemetrexed or cisplatin exerts long-lasting anti-tumor effect in EGFR-mutated pre-clinical models of NSCLC
por: La Monica, Silvia, et al.
Publicado: (2019)

Combined use of anti-ErbB monoclonal antibodies and erlotinib enhances antibody-dependent cellular cytotoxicity of wild-type erlotinib-sensitive NSCLC cell lines
por: Cavazzoni, Andrea, et al.
Publicado: (2012)

Effect of the JAK/STAT Inhibitor Tofacitinib on Macrophage Cholesterol Metabolism
por: Adorni, Maria Pia, et al.
Publicado: (2023)

CDK4/6 inhibitors improve the anti-tumor efficacy of lenvatinib in hepatocarcinoma cells
por: Digiacomo, Graziana, et al.
Publicado: (2022)

Pemetrexed Enhances Membrane PD-L1 Expression and Potentiates T Cell-Mediated Cytotoxicity by Anti-PD-L1 Antibody Therapy in Non-Small-Cell Lung Cancer
por: Cavazzoni, Andrea, et al.
Publicado: (2020)

Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
por: Khalifa, Amr, et al.
Publicado: (2023)

Author Correction: Cyclic fasting bolsters cholesterol biosynthesis inhibitors’ anticancer activity
por: Khalifa, Amr, et al.
Publicado: (2023)

Expanding the Arsenal of FGFR Inhibitors: A Novel Chloroacetamide Derivative as a New Irreversible Agent With Anti-proliferative Activity Against FGFR1-Amplified Lung Cancer Cell Lines
por: Fumarola, Claudia, et al.
Publicado: (2019)

Drug-drug interactions in polypharmacy patients: The impact of renal impairment
por: Papotti, Bianca, et al.
Publicado: (2021)

Metabolism of the EGFR tyrosin kinase inhibitor gefitinib by cytochrome P450 1A1 enzyme in EGFR-wild type non small cell lung cancer cell lines
por: Alfieri, Roberta R, et al.
Publicado: (2011)

Shiga Toxin 1, as DNA Repair Inhibitor, Synergistically Potentiates the Activity of the Anticancer Drug, Mafosfamide, on Raji Cells
por: Brigotti, Maurizio, et al.
Publicado: (2013)

Trastuzumab emtansine delays and overcomes resistance to the third-generation EGFR-TKI osimertinib in NSCLC EGFR mutated cell lines
por: La Monica, Silvia, et al.
Publicado: (2017)

PCSK9 Affects Astrocyte Cholesterol Metabolism and Reduces Neuron Cholesterol Supplying In Vitro: Potential Implications in Alzheimer’s Disease
por: Papotti, Bianca, et al.
Publicado: (2022)

Curcumin reverses doxorubicin resistance via inhibition the efflux function of ABCB4 in doxorubicin-resistant breast cancer cells
por: Wen, Chunjie, et al.
Publicado: (2019)

Three-Dimensional (3D) Printed Silver Nanoparticles/Alginate/Nanocrystalline Cellulose Hydrogels: Study of the Antimicrobial and Cytotoxicity Efficacy
por: Bergonzi, Carlo, et al.
Publicado: (2020)

STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1
por: Li, Zhaoqing, et al.
Publicado: (2021)

Hypertonic Stress and Amino Acid Deprivation Both Increase Expression of mRNA for Amino Acid Transport System A
por: Alfieri, Roberta R., et al.
Publicado: (2005)

circRNA_103615 contributes to tumor progression and cisplatin resistance in NSCLC by regulating ABCB1
por: Liang, Hongguang, et al.
Publicado: (2021)

HDL Proteome and Alzheimer’s Disease: Evidence of a Link
por: Marsillach, Judit, et al.
Publicado: (2020)

Corrigendum: STAT5a Confers Doxorubicin Resistance to Breast Cancer by Regulating ABCB1
por: Li, Zhaoqing, et al.
Publicado: (2022)

Iron Promotes Cardiac Doxorubicin Retention and Toxicity Through Downregulation of the Mitochondrial Exporter ABCB8
por: Menon, Archita Venugopal, et al.
Publicado: (2022)

High Density Lipoprotein Cholesterol Efflux Capacity and Atherosclerosis in Cardiovascular Disease: Pathophysiological Aspects and Pharmacological Perspectives
por: Adorni, Maria Pia, et al.
Publicado: (2021)

ABCB1 polymorphism as prognostic factor in breast cancer patients treated with docetaxel and doxorubicin neoadjuvant chemotherapy
por: Kim, Hee-Jun, et al.
Publicado: (2015)

Alcohol Pattern Consumption Differently Affects the Efficiency of Macrophage Reverse Cholesterol Transport in Vivo
por: Greco, Daniela, et al.
Publicado: (2018)

Isolation and Characterization of Circulating Tumor Cells in Squamous Cell Carcinoma of the Lung Using a Non-EpCAM-Based Capture Method
por: Bozzetti, Cecilia, et al.
Publicado: (2015)

Doxorubicin—An Agent with Multiple Mechanisms of Anticancer Activity
por: Kciuk, Mateusz, et al.
Publicado: (2023)

Erdafitinib Resensitizes ABCB1-Overexpressing Multidrug-Resistant Cancer Cells to Cytotoxic Anticancer Drugs
por: Wu, Chung-Pu, et al.
Publicado: (2020)

Sapitinib Reverses Anticancer Drug Resistance in Colon Cancer Cells Overexpressing the ABCB1 Transporter
por: Gao, Hai-Ling, et al.
Publicado: (2020)

Proprotein Convertase Subtilisin/Kexin Type 9, Brain Cholesterol Homeostasis and Potential Implication for Alzheimer’s Disease
por: Adorni, Maria Pia, et al.
Publicado: (2019)

YES1 and MYC Amplifications as Synergistic Resistance Mechanisms to Different Generation ALK Tyrosine Kinase Inhibitors in Advanced NSCLC: Brief Report of Clinical and Preclinical Proofs
por: Minari, Roberta, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_tn5pk7c9v1fbc25cf3osooi9kk